1 citations
,
January 2023 in “Annals of Indian Academy of Neurology” Recognizing CVG can help diagnose systemic amyloidosis early.
5 citations
,
May 2025 in “Journal of the American Academy of Dermatology” July 2026 in “Dermatology and Therapy” Baricitinib and ritlecitinib are both effective and safe for treating severe alopecia areata.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
1 citations
,
March 2023 in “Skin” Baricitinib helps patients with severe alopecia areata regrow hair.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
Stroma structural changes cause large pores and skin laxity, regardless of age or ethnicity.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
8 citations
,
August 2012 in “Clinical, cosmetic and investigational dermatology” Doublebase gel hydrates skin better and is preferred by most users over Aqueous cream.
36 citations
,
March 2023 in “Bioengineering” Barbed sutures improve surgical outcomes and efficiency but are limited by cost and strength issues.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
April 2026 in “Journal of Pharmacy Practice” Improper vitamin use after bariatric surgery can cause acne.
November 2023 in “Bioengineering” AMT® is effective and safe for early-stage knee osteoarthritis.
87 citations
,
March 2000 in “American Journal of Clinical Dermatology” Alpha-hydroxy acids, like glycolic acid, safely improve skin issues and work on all skin types.
June 2016 in “American Journal of Cardiology” Endovascular repair and open surgery for abdominal aortic aneurysms both result in a temporary decline in physical health, with no significant mental health difference, and a return to near normal health in 90 days.
1 citations
,
November 2024 in “Saudi Pharmaceutical Journal” Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
Baricitinib works better than methotrexate for severe alopecia areata.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
December 2018 in “Dermatologic Surgery” Using a 25% trichloroacetic acid peel improves dermabrasion results in vitiligo surgery.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
3 citations
,
February 2022 in “Journal of the American Academy of Dermatology” Black patients with a specific type of hair loss have a much higher chance of lacking enough vitamin D.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Baricitinib is used for severe alopecia areata after trying corticosteroids or other JAK inhibitors.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.